<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665648</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-CLEAN</org_study_id>
    <nct_id>NCT04665648</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention</brief_title>
  <acronym>CLEAN</acronym>
  <official_title>Impact of Intravenous Administration of Nicorandil as Adjuncts to Reperfusion Treatment for Acute ST Segment Elevation Myocardial Infarction: a Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluate the efficacy and safety of intravenous administration of&#xD;
      nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute&#xD;
      myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention&#xD;
      (PCI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>12 month after primary PCI</time_frame>
    <description>cardiac death, myocardial reinfarction, target vessel revascularization, unplanned hospitalization for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of slow re-flow/no-reflow</measure>
    <time_frame>3 minutes after primary PCI</time_frame>
    <description>final coronary flow in the culprit artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate fo complete ST-segment resolution</measure>
    <time_frame>2 hours after primary PCI</time_frame>
    <description>ST-segment resolution &gt;50% in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months after primary PCI</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial reinfarction</measure>
    <time_frame>12 months after primary PCI</time_frame>
    <description>Myocardial reinfarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 months after primary PCI</time_frame>
    <description>Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospitalization for heart failure</measure>
    <time_frame>12 months after primary PCI</time_frame>
    <description>Unplanned hospitalization for heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorandil</intervention_name>
    <description>6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years;&#xD;
&#xD;
          -  acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  systolic blood pressure&lt;100mmHg;&#xD;
&#xD;
          -  cardiac shock;&#xD;
&#xD;
          -  aortic dissection;&#xD;
&#xD;
          -  history of myocardial infarction or percutaneous coronary intervention or coronary&#xD;
             artery bypass grafting (&lt;6 month);&#xD;
&#xD;
          -  history of the treatment of nicorandil (&lt;6 month);&#xD;
&#xD;
          -  history of intravenous nitrates before percutaneous coronary intervention;&#xD;
&#xD;
          -  contraindicated or intolerable to nicorandil;&#xD;
&#xD;
          -  pregnant or lactation period;&#xD;
&#xD;
          -  patients with an estimated survival time of less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dong Huang</last_name>
    <phone>+8613512142875</phone>
    <email>huang.dong@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Huang</last_name>
      <phone>13512142875</phone>
      <email>huang.dong@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007 Oct 27;370(9597):1483-93. Erratum in: Lancet. 2008 Dec 22;370(9605):2102.</citation>
    <PMID>17964349</PMID>
  </results_reference>
  <results_reference>
    <citation>Kawai Y, Hisamatsu K, Matsubara H, Dan K, Akagi S, Miyaji K, Munemasa M, Fujimoto Y, Kusano KF, Ohe T. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 2009 Apr;30(7):765-72. doi: 10.1093/eurheartj/ehp077. Epub 2009 Mar 10.</citation>
    <PMID>19276198</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu M, Huang Z, Xie H, Zhou Z. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One. 2013 Oct 22;8(10):e78231. doi: 10.1371/journal.pone.0078231. eCollection 2013. Review.</citation>
    <PMID>24167609</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ge Junbo</investigator_full_name>
    <investigator_title>Director, Dept. of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

